• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

Ventyx bags $114M to test drugs against hot immunology targets

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Mar 09, 2021 at 11:02: AM
via Ventyx Biosciences has exited stealth mode with $114 million to fund development of immunology programs. The venBio Partners-led financing will support a pipeline led by a S1P1R modulator that is in clinical development as a treatment for inflammatory bowel disease (IBD).

article source
 




Top Bottom
Back
Quote